Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic HB-adMSCs vs Placebo for Parkinson's Disease
NCT04995081Phase 2Completed
- Sponsor
- Hope Biosciences
- Start
- Jul 2021
- Primary completion
- Oct 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic HB-adMSCs in Parkinson's disease (PD), sponsored by Hope Biosciences. Started Jul 2021; status: completed.
02
Drugs
allogeneic HB-adMSCs
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04995081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04995081.